No Data
H.C. Wainwright Maintains Aldeyra Therapeutics(ALDX.US) With Buy Rating, Maintains Target Price $10
Aldeyra Therapeutics' Reproxalap: Promising Pipeline and Strategic Partnerships Justify Buy Rating
Aldeyra Therapeutics | 10-Q: Quarterly report
Aldeyra Therapeutics Selected to Present at the Disruptive Innovations Symposium During the OSN New York Retina 2024 Meeting
Oppenheimer Maintains Aldeyra Therapeutics(ALDX.US) With Buy Rating, Raises Target Price to $12
Laidlaw Initiates Aldeyra Therapeutics(ALDX.US) With Buy Rating, Announces Target Price $11
No Data
No Data